Santen Pharmaceutical (OTCMKTS:SNPHY) Cut to “Neutral” at Credit Suisse Group

Santen Pharmaceutical (OTCMKTS:SNPHY) was downgraded by Credit Suisse Group from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday, The Fly reports.

Shares of OTCMKTS SNPHY opened at $18.42 on Monday. The stock’s fifty day moving average price is $18.29 and its two-hundred day moving average price is $17.90. Santen Pharmaceutical has a one year low of $13.00 and a one year high of $20.18.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-126 that is in Phase 2b clinical trial; DE-128, which is in Phase 2/3 clinical trial; DE-130A that is in Phase III clinical trial; and DE-117.

Further Reading: Understanding the different types of bonds

The Fly

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.